Safety and Tolerability Study of COVA322 in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is a randomised, double-blind, placebo-controlled, sequential, ascending
single-dose, parallel group study to evaluate safety, tolerability, biological activity, and
systemic exposure of COVA322 (tumor necrosis factor alpha (TNF-α) / interleukin 17 A (IL-17A)
antibody fusion protein) in patients with stable chronic moderate-to-severe plaque psoriasis.
Patients will receive ascending single-doses of COVA322 or placebo as a constant-rate i.v.
infusion, followed by 12 weeks of evaluation.